Page 105 - Read Online

Ray et al. J Cancer Metastasis Treat 2020;6:9 I http://dx.doi.org/10.20517/2394-4722.2020.16 Page 9 of 9

Authors’ contributions
Substantial contributions to the conception or design of the manuscript, writing manuscript, revising it
critically for important intellectual content and to be accountable for all aspects of the work in ensuring
that questions related to the accuracy or integrity of the manuscript: Ray MD
Data collection, data analysis, data curation, drafting the work, manuscript writing, editing, conceptualisation,
technical and material support, study supervision, revising it critically for important intellectual content and
proofreading with final approval of the manuscript version to be published: Kumar N
Data collection, data analysis, drafting the work, manuscript writing, drawing pictorial depiction and
formatting, editing, provided technical, and material support: Kuppusamy R
Manuscript writing and final approval of manuscript version to be published: Garg R
Have read and approved the manuscript: Ray MD, Kuppusamy R, Kumar N, Garg R

Availability of data and materials
The data (operative pictures, further case details, follow up data) to support the findings of this study are
available on request from the corresponding authors.

Financial support and sponsorship
None.

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
The study has been performed following the “Declaration of Helsinki” and approved by the “institutional
ethics committee, AIIMS, New Delhi, India” vide reference no: IEC-592/03.11.2017, AA-3/29. Informed
consent to participate in the study has been obtained from participants.

Consent for publication
Not applicable. No identifying images or other personal or clinical details of participants are presented in
the manuscript that compromise anonymity.

Copyright
© The Author(s) 2020.

REFERENCES
1. Mulier S, Claes JP, Dierieck V, Amiel JO, Pahaut JP, et al. Survival benefit of adding Hyperthermic IntraPEritoneal Chemotherapy (HIPEC)
at the different time-points of treatment of ovarian cancer: review of evidence. Curr Pharm Des 2012;18:3793-803.
2. Chua TC, Yan TD, Saxena A, Morris DL. Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic
intraperitoneal chemotherapy still be regarded as a highly morbid procedure?: a systematic review of morbidity and mortality. Ann Surg
2009;249:900-7.
3. Sugarbaker PH. Peritonectomy procedures. Cancer Treat Res 2007;134:247-64.
4. Dehal A, Smith JJ, Nash GM. Cytoreductive surgery and intraperitoneal chemotherapy: an evidence-based review-past, present and
future. J Gastrointest Oncol 2016;7:143-57.
5. Overgaard J. Effect of hyperthermia on malignant cells in vivo. A review and a hypothesis. Cancer 1977;39:2637-46.
6. van Driel WJ, Koole SN, Sikorska K, Schagen van Leeuwen JH, Schreuder HWR, et al. Hyperthermic intraperitoneal chemotherapy in
ovarian cancer. N Engl J Med 2018;378:230-40.
7. Spiliotis J, Halkia E, Lianos E, Kalantzi N, Grivas A, et al. Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a
prospective randomized phase III study. Ann Surg Oncol 2015;22:1570-5.
8. Sugarbaker PH, Chang D, Stuart OA. Hyperthermic intraoperative thoracoabdominal chemotherapy. Gastroenterol Res Pract
2012;2012:623417.
9. Erasmus JJ, Goodman PC, Patz EF Jr. Management of malignant pleural effusions and pneumothorax. Radiol Clin North Am
2000;38:375-83.